GLP-1 eligibility: who may qualify and what clinicians review

GLP-1 eligibility is not a simple yes-or-no question. The FDA-approved indications set a baseline, but a responsible prescriber evaluates far more than BMI before writing a prescription — including medical history, contraindications, concurrent medications, lab results, and whether telehealth is an appropriate care setting for the specific patient.

FDA-approved indications for weight management

Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are FDA-approved for chronic weight management in adults with a BMI of 30 kg/m² or greater (obesity), or a BMI of 27 kg/m² or greater (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea. Saxenda (liraglutide 3.0 mg) carries the same BMI criteria.

Wegovy also has an approved cardiovascular indication: it is indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight, based on the SELECT trial results published in 2023.

Absolute contraindications

All GLP-1 receptor agonists carry contraindications that should disqualify a patient from treatment regardless of BMI. These are listed in the prescribing information for each drug:

• Personal or family history of medullary thyroid carcinoma (MTC). Both semaglutide and tirzepatide carry a boxed warning about thyroid C-cell tumors observed in rodent studies.

• Multiple endocrine neoplasia syndrome type 2 (MEN 2).

• Known hypersensitivity to the active substance or any excipients. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported.

• Pregnancy. GLP-1 RAs may cause fetal harm based on animal data. Women of childbearing potential should use contraception during treatment and discontinue the medication at least 2 months before a planned pregnancy (semaglutide has a long half-life of approximately 7 days).

Relative contraindications and caution areas

Beyond absolute contraindications, clinicians evaluate several conditions that may affect whether a specific GLP-1 medication is appropriate or require closer monitoring:

• History of pancreatitis: GLP-1 RAs have been associated with acute pancreatitis. Patients with a history of pancreatitis may be at increased risk.

• Gallbladder disease: clinical trials showed higher rates of cholelithiasis and cholecystitis in patients on GLP-1 RAs, particularly with rapid weight loss.

• Severe gastrointestinal disease: gastroparesis, inflammatory bowel disease, or history of bowel obstruction may worsen with drugs that slow gastric emptying.

• Diabetic retinopathy: semaglutide has been associated with early worsening of diabetic retinopathy in patients with pre-existing disease, particularly with rapid glucose improvements.

• Renal impairment: dehydration from GI side effects (nausea, vomiting, diarrhea) can precipitate acute kidney injury, especially in patients with pre-existing chronic kidney disease.

• Concurrent use of insulin or sulfonylureas: combination increases hypoglycemia risk and requires dose adjustment of the diabetes medication.

• History of suicidal behavior or ideation: the FDA has required monitoring for suicidal ideation based on post-marketing reports, though a causal relationship has not been established.

What telehealth intake forms typically screen

A thorough telehealth intake should collect enough information for a clinician to evaluate all of the above. The standard intake includes:

• Demographics: age, sex, height, weight (for BMI calculation).

• Weight history: highest adult weight, prior weight-management attempts (diet, exercise programs, other medications, bariatric surgery).

• Medical history: cardiovascular disease, diabetes, thyroid disorders, pancreatic disease, gallbladder disease, kidney disease, liver disease, eating disorders, mental health conditions.

• Family history: thyroid cancer (particularly medullary), MEN 2, pancreatic cancer.

• Current medications: all prescription and OTC drugs, particularly insulin, sulfonylureas, blood thinners, and oral contraceptives.

• Pregnancy status and plans: current pregnancy, breastfeeding, or plans to conceive.

• Prior GLP-1 experience: previous use of semaglutide, tirzepatide, liraglutide, or other GLP-1 RAs, including doses reached and reasons for discontinuation.

• Allergies and adverse drug reactions.

Lab work: what clinicians may require

Not all telehealth programs require labs before starting treatment, but a thorough program may request recent results or order new tests:

• HbA1c and fasting glucose: to screen for or monitor diabetes, which affects drug selection and monitoring.

• Thyroid panel (TSH, free T4): baseline thyroid function given the thyroid C-cell tumor warnings.

• Comprehensive metabolic panel: kidney function (eGFR, creatinine) and liver function (ALT, AST) to identify patients who need closer monitoring.

• Lipid panel: baseline cardiovascular risk assessment.

Insurance coverage versus cash-pay eligibility

Insurance eligibility and clinical eligibility are different things. Many commercial insurance plans cover Wegovy or Zepbound but impose step therapy requirements (documented failure of diet and exercise, sometimes prior authorization showing a certain number of months of lifestyle intervention). Medicare Part D began covering anti-obesity medications following the TREAT Act provisions, though formulary placement and prior authorization requirements vary by plan.

Cash-pay programs through telehealth providers typically have simpler eligibility criteria — often just the BMI thresholds — because the insurance step-therapy requirements do not apply. However, clinical contraindication screening should be equally rigorous regardless of payment method.

What to prepare before your intake

• An accurate, complete medication list including dosages.

• Recent lab results if available (within 6-12 months).

• A summary of prior weight-management attempts and outcomes.

• Your primary care provider's contact information (some programs require PCP coordination for complex cases).

• Honest answers about medical history — omitting conditions like pancreatitis or thyroid cancer history can lead to unsafe prescribing.